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AtherosclerosisanditsassociatedcomplicationsrepresentmajorcausesofmorbidityandmortalityintheindustrializedorWestern
countries. Monocyte chemoattractant protein-1 (MCP-1) is critical for the initiating and developing of atherosclerotic lesions.
Interleukin-8 (IL-8), a CXC chemokine, stimulates neutrophil chemotaxis. Ticlopidine is one of the antiplatelet drugs used to
prevent thrombus formation relevant to the pathophysiology of atherothrombosis. In this study, we found that ticlopidine dose-
dependently decreased the mRNA and protein levels of TNF-α-stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1
(VCAM-1) in human umbilical vein endothelial cells (HUVECs). Ticlopidine declined U937 cells adhesion and chemotaxis as
compared to TNF-α stimulated alone. Furthermore, the inhibitory eﬀects were neither due to decreased HUVEC viability, nor
through NF-kB inhibition. These results suggest that ticlopidine decreased TNF-α induced MCP-1, IL-8, and VCAM-1 levels in
HUVECs, and monocyte adhesion. Therefore, the data provide additional therapeutic machinery of ticlopidine in treatment and
prevention of atherosclerosis.
Copyright © 2009 Chaur-Jong Hu et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Atherosclerosis is a chronic inﬂammatory disease. The
recruitment of inﬂammatory cells is an essential step in
the development and progression of the disease. It is
well documented that monocyte adhesion, migration, and
inﬁltration into the atheroma are crucial to the pathogenesis
of atherosclerosis. Chemokines play an important role in
recruiting monocytes and lymphocytes into the atheroscle-
rotic lesions [1–4].
We have monocyte chemoattractants protein-1 (MCP-
1) is a 14-kDa glycoprotein of the CC chemokine family
and a potent chemotactant for monocyte, T cell, and NK
cell recruitment [5–7]. MCP-1 is expressed by monocytes,
smooth muscle cells, and endothelial cells, including human
vascular endothelial cells (HUVECs) in response to several
diﬀerent stimuli such as interleukin (IL)-1β, tumor necrosis
factor (TNF)-α,a n da n g i o t e n s i nI I[ 8–10]. MCP-1 has been
found as one of the key factors in the initiation of the
inﬂammatory process of atherogenesis [1, 5, 11]. MCP-1 has2 Journal of Biomedicine and Biotechnology
been detected in macrophage-rich areas of atherosclerotic
lesions [12, 13], and MCP-1 mRNA expression increases in
endothelial cells, macrophages, and vascular smooth muscle
cellsintheatheroscleroticarteriesfromthepatientsreceiving
bypass revascularization [14]. Therefore, MCP-1 is critical to
the initiation and development of atherosclerotic lesions.
IL-8, another important chemokine, belongs to a CXC
chemokine family. It has been found to act mainly on neu-
trophils [15–17] but it also was found to recruit monocytes
in some studies [2, 18]. IL-8 was found in human atheroma
[19], and is implicated in atherosclerosis development [4].
Mice lacking IL-8 receptors are less susceptible to form
atherosclerosis and have fewer monocytes accumulated in
vascularlesions[16].Inadditiontochemokines,vascularcell
adhesion molecule-1 (VCAM-1) mediates adhesion to and
rollingofmonocytesalongendothelialcells[20, 21].Overex-
pression of VCAM-1 was found in atherosclerotic lesion [22,
23], and deﬁciency of VCAM-1Ig domain 4 reduces mono-
cyte migration and inhibits atheroselerotic lesion formation
in mice [24]. Therefore, chemokines together with adhesion
molecules play a key role in development of atherosclerosis.
Ticlopidine is widely used in the prevention of thrombo-
sis during and after coronary stent placement and has been
found to be at least equivalent to aspirin in the prevention
of events in patients with cerebrovascular disease [25]. In
several studies, ticlopidine even appeared to be slightly more
eﬀective than aspirin in preventing serious vascular occlusive
events in patients with atherosclerotic disease [26]. The
ticlopidine-aspirin stroke study (TASS) demonstrated that
ticlopidine was a more eﬀective agent than aspirin for the
prevention of recurrent transient ischemic attacks [27].
In this study, in addition to the antiplatelet function,
we examined the eﬀects of ticlopidine on the expressions
of MCP-1, IL-8, and VCAM-1 in an in vitro atherosclerosis
model which consists of TNF-α-stimulated HUVECs to
evaluate the possible role of ticlopidine for its potential
antiatherosclerotic therapy.
2.MaterialsandMethods
2.1. Materials. Ticlopidine was purchased from Sigma (St.
Louis, MO), and U937 cells from Culture Collection and
Research Center CCRC No. 68002 (Hsinchu, Taiwan). All
reagents were of analytical grade.
2.2. Cell Culture. We purchased HUVECs and endothelial
cell growth medium (EGM-2, CC3156) from Clonetics (San
Diego,CA),whichcontained10%fetalbovineserum,hydro-
cortisone, hFGF-B, vEGF, R3-IGF-I, ascorbic acid, hEGF,
GA-1000, and heparin. HUVECs which were used between
passages 1 and 6, were maintained in EGM-2 medium in a
humidiﬁed chamber containing 5% CO2 at 37◦C. Cells were
cultured in 6-well or 24-well plates until conﬂuent and were
washed twice and incubated with serum-free medium for
12 hours before diﬀerent concentrations of ticlopidine (0.1,
2, 10, 30μg/mL) were added. After being incubated for 12
hours, cells were stimulated with TNF-α (10ng/mL) (R&D
Systems;Minneapolis,MN)for24hoursforMCP-1andIL-8
expression. After incubation, the supernatants were collected
for ELISA analysis, and the cells were used for RNA isolation.
2.3. MTT Assay for Cell Viability. Mitochondrial dehydro-
genase activity, which reduces 3-(4,5-dimethyl-thiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT, Sigma, St. Louis,
USA)inactivemitochondriatopurpleformazan,wasusedto
determine cell survival in a colorimetric assay. Cell viability
was calculated accordingly
Cell viability = Absorbance

sample tested

/Absorbance
×

medium only

×100%.
(1)
2.4. RNA Isolation, Reverse Transcription-Polymerase Chain
Reaction (RT-PCR) and Real-Time PCR Analysis. Total RNA
was extracted from 1 ×106 cells according to manufacturer’s
instructions (Life Technologies, Grand Island, NY). The
concentrations of the RNA samples were measured with
a spectrophotometer (GeneQuant II, Pharmacia Biotech)
to determine the OD 260 and OD260/280 values. In total,
5μg of RNA samples was reverse transcribed with an
oligo-dT primer to synthesize ﬁrst-strand cDNA according
to a previous report [28]. cDNA was ampliﬁed by PCR
with speciﬁc primers for MCP-1 and IL-8; primers for
MCP-1 were 5 -GCTCATAGCAGCCACCTTCATTC-3 
(sense) and 5 -TGCAGATTCTTGGGTTGTGGAG-3 
(antisense). Primers for IL-8 were 5 -ATGACTTCCAAG
CTGGCCGTGGCT-3  (sense) and TCTCAGCCC
TCTTCATCAAAAACTTCTC-3  (anti-sense). The PCR
conditions used for MCP-1 and IL-8 were based on the
previous reports [29, 30]. Primers for human β-actin were
5 -ATGGATGATGATATCGCCGCG-3  (sense) and 5 -
CATGAAGCATTTGCGGTGGACGATGGAGGGGCC-
3  whichusedasaninternalcontrol.PCRproductswerevisu-
alized by agarose gel electrophoresis. Photos were scanned by
Scan Maker II sp and analyzed by Image-ProR Plus software.
Real-timePCRampliﬁcationemployedreagentssupplied
in a DyNAmo Flash SYBR Green qPCR Master Mix Kit
(Finnzymes, Finland), and each reaction contained 20ng of
cDNA, 10pmol each of both primers, and 5μL of SYBR
Green master mix.
The following gene-speciﬁc primer sets were used:
MCP-1 5 -CCCCAGTCACCTGCTGTTAT-3  (sense)
and 5 -AGATCTCCTTGGCCACAATG-3  (antisense)
[31]; IL-8, 5 -GTGCAGTTTTGCCAAGGAGT-3  (sense)
and 5 -TAATTTCTGTGTTGGCGCAG-3  (antisense)
[32]; VCAM-1, 5 -TCTCATTGACTTGCAGCACC-3 
(sense) and 5 -TTCTTGCAGCTTTGTGGATG-3 .
(antisense) [33]; β-actin, 5 -CCCTTTTTGTCCCCCAAC-
3  (sense) and 5 -CTGGTCTCAAGTCAGTGTACAGGT-
3  (antisense) [34]. Speciﬁc mRNA levels were quantiﬁed by
real-time RT-PCR (MJ Research DNA Ebgine OPTICON
2) using β-actin levels for normalization. The ampliﬁcation
conditions were 10 minutes at 95◦C, 40 cycles of 10 secondsJournal of Biomedicine and Biotechnology 3
at 95◦C, and 1 minute at 60◦C. The relative quantity of
MCP-1, IL-8, and VCAM-1 transcripts was calculated
using the 2− Ct method. Data were ﬁrst normalized to the
corresponding β-actin levels, and then expressed as fold
increase with relative to untreated controls. All samples were
assayed in triplicates. Data represents mean ± SEM of three
independent experiments.
2.5. MCP-1, IL-8, and VCAM-1 Analysis by Enzyme-Linked
Immunosorbent Assay (ELISA). Concentrations of MCP-1,
IL-8, and VCAM-1 were quantiﬁed using commercially
available DuoSet ELISA development system (R&D Sys-
tems; Minneapolis, MN) according to the manufacturer’s
instructions. The sensitivity for MCP-1, IL-8, and VCAM-
1 was 6.25–1000pg/mL, 31.25–2000pg/mL and 15.625–
1000pg/mL, respectively. All the samples were tested in the
duplicated wells.
2.6. U937 Adhesion Assay. The adhesion assay was modiﬁed
as described in [35]. In brief, U937 cells were labeled
with 2 ,7  -bis(2-carboxyethyl)-5(6)-carboxyﬂuorescein
acethoxymethyl ester (BCECF/AM, 10μg/mL; Sigma, MO)
for 30 minutes at 37◦C. RPMI-1640 containing 2% FCS
was added to stop the reaction, and cells were suspended
in M199 medium. HUVECs were cultured in 24-well plates
until conﬂuent, at which time diﬀerent concentrations of
ticlopidine were added and then incubated for an additional
12 hours. After incubation, TNF-α (10ng/mL) was added
to the wells and incubated for another 24 hours. Then
HUVECs were coincubated with 106BCECF/AM-labelled
U937 cells/well for 30 minutes at 37◦C. Nonadhering
U937 cells were removed, and the 24-well plates were
washed twice with M199 medium. The plates were
inverted and centrifuged for 2200rpm 5minutes to remove
M199 medium. Cells were lysed in 0.1% Triton X-100
in 0.1mol/L Tris buﬀer. Fluorescence was measured with
an F-4500 Fluorescence Spectrophotometer (HITACHI)
(using excitation at 510 nm and emission at 531 ± 25nm).
The areas under emission wavelength were calculated for
the ﬂuorescence intensity of adherent cells using F-4500
software. Media from untreated cells were used to determine
the basal adhesion.
2.7. Chemotaxic Assay. HUVECs were seeded in the upper
chamber of a transwell tissue culture insert (8μmp o r e
size) (Costar Cambridge, MA) until they reached conﬂuent
density. Diﬀerent concentrations of ticlopidine were added
to the upper wells and incubated for 30minutes at 37◦C,
5% CO2 incubator. Media from the upper chamber were
aspirated and U937 cells (106 cell/100μl/well) were added to
the upper chambers. Recombinant IL-8 (rIL-8) (50ng/mL)
and rMCP-1 (50ng/mL) were added into the lower wells.
Theplates werethen incubated in a 37◦C, 5% CO2 incubator
for 1.5hours. M199 media containing 0.5mM EDTA were
used for washing the U937 cells from the lower part of
the membrane to lower wells. Cells in the lower wells were
collected by centrifugation at 3000g for 5minute and direct
cell counting was conducted under microscope.
2.8.WesternBlotAnalysisofNF-Kbp65SubunitTranslocation.
HUVECs were incubated with diﬀerent concentrations of
ticlopidine and 100μg/mL of aspirin, which was added
as the control. Cells were stimulated with or without
TNF-α (10ng/mL) for 30minutes and nuclear proteins
were prepared. Brieﬂy, the cells were washed with ice-cold
PBS, lyzed in a hypotonic lysis buﬀer containing protease
inhibitors (20mM Hepes, 10mM KCl, 1mM MgCl2,0 . 5 %
NP-40, 0.5mM DTT, 10mM NaF, 1mM PMSF, 10μg/mL
Aprotinin, 10μg/mL Leupeptin, pH7.4), and incubated on
ice for 5minutes. After incubation, the lysate wascentrifuged
at 10,000xg for 5minutes to separate nucleus pellet from
supernatant (cytosolic part). The supernatant was saved.
The resultant pellet was, subsequently, washed with the
hypotoniclysisbuﬀertwice,suspendedinahypertonicbuﬀer
(20mM HEPES (pH 7.4), 10mM KCl, 1mM MgCl2,0 . 4M
NaCl, 0.5mM DTT, 10mM NaF, 1mM PMSF, 10mg/mL
Aprotinin, 10mg/mL Leupeptin), and vigorously vortex for
30minutes. After incubation on ice for 15minutes, the
nuclear extract was collected by centrifuging at 25,000xg,
4◦C for 30minutes and transferred to new microcentrifuge
tubes.Theconcentrationofthenuclearandcytosolicextracts
was determined by protein assay (Bio-Rad). Thirtyμg/mL
of protein were resolved on 10% SDS-PAGE and were
transferred to nitrocellulose membrane. The blots were
immediately blocked with 5% nonfat milk-containing Tris-
buﬀered saline and probed with anti-NF-kB p65 Ab (1 :
1000; Santa Cruz Biotechnology, Inc.) for 1.5hours at room
temperature. The resultant immunocomplex was visualized
in chemoluminescence enhanced system (Amersham). The
same blot was restriped and probed with anti-B23 polyclonal
antibody for nuclear protein loading control (1 : 1000
dilution; Santa Cruz Biotechnology, Inc).
2.9. Statistical Analysis. We used Student’s t-test to analyze
the diﬀerences of continuous variables which were presented
as the mean ± SEM. The diﬀerences were considered
signiﬁcant if the P-value was smaller than 0.05.
3. Results
3.1. Ticlopidine Decreased TNF-α-Induced MCP-1 mRNA and
ProteinLevels in HUVECs. The concentrationsof ticlopidine
used in this study were physiological concentrations accord-
ing to the Klein-Soyer et al. [36]. The daily recommended
dose of ticlopidine is 250–500mg, demonstrated plasma
concentrations of the drug in low microgram/mL range [37],
and concentrations of 10–30μg/mL are pharmacologically
irrelevant. The MTT assay was performed to investigate
whether ticlopidine aﬀect the growth of HUVECs. As shown
in Figure 1(a), more than 85% of the cells remained viable
after treatment of TNF-α combined with diﬀerent con-
centrations ofticlopidine 0.1, 2, and 10μg/mL respectively,
indicating thattherewerenosigniﬁcanttoxiceﬀectsdetected
as compared to the controls (100%). When HUVECs were
treated with 30μg/mL of ticlopidine, the cell viability was
above 65% as compared to the controls.4 Journal of Biomedicine and Biotechnology
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Figure 1: Reduction of MCP-1 mRNA and protein levels by ticlopidine in HUVECs. HUVECs were incubated with serum-free medium
for 12hours before diﬀerent concentrations of ticlopidine were added, after 12hours incubation cells were stimulated with/without TNF-α
(10ng/mL) for another 24hours. (a) Cell growth was analyzed by MTT. Results are mean ± SEM (n = 3). (b) Total RNA was extracted and
analyzed by RT-PCR. Lane 1, without TNF-α;l a n e2 ,T N F - α (10ng/mL) alone; lane 3, TNF-α + ticlopidine (0.1μg/mL); lane 4 TNF-α +
ticlopidine (30μg/mL); M denotes molecular size marker. The lower panel is β-actin as internal control. Results are representative of one of
three independent experiments. (c) Relative amount of MCP-1 mRNA level was determined by quantitative real-time RT-PCR. (d) Culture
supernatants were analyzed by ELISA. Data are expressed as the mean ± SEM of duplicate wells and are representative of ﬁve individual
experiments. Signiﬁcantly diﬀerent versus TNF-treated alone ∗P < .05, ∗∗P < .001.
WetestedwhetherticlopidinewasabletoregulateMCP-1
level elicited by TNF-α on HUVECs. By using speciﬁc MCP-
1 primers, RT-PCR analysis detected a single band with the
expected size of 297 base pairs (bp). As shown in Figure 1(b),
MCP-1 mRNA level decreased signiﬁcantly when treated
with 30μg/mL of ticlopidine (lane 4) as compared to those
with 0.1μg/mL (lane 3) and without treatment (lane 2). In
addition, weanalyzedthelevelofMCP-1mRNAusingquan-
titative real-time PCR. We found that MCP-1 mRNA was
up-regulatedinTNF-αtreatedHUVECs,anddownregulated
by ticlopidine at examined concentrations (Figure 1(c)).
These results indicated that ticlopidine declined the MCP-
1 mRNA level induced by TNF-αon HUVECs. The negative
controls for PCR, either without cDNA or without reverse
transcriptase, were performed simultaneously.
Furthermore, our ELISA data indicated that TNF-α
signiﬁcantly upregulated the level of MCP-1 (28,410 ±
2,088pg/mL) secretion in HUVECs as compared to that in
samples without TNF-α treatment (619.2 ± 54.02pg/mL,
n = 6) (P<. 0001). TNF-α-stimulated MCP-1 secretion
was reduced when cells were pretreated with ticlopidine in
a dose dependent manner (Figure 1(d)). Doses of ticlopidine
at as low as 0.1 μg / m Ls h o w e do b v i o u sr e d u c t i o ni nM C P -
1 secretion by 15.8% (23,920 ± 2,387pg/mL) (P = .0416)
(Figure 1(d)).
3.2. Ticlopidine Decreased TNF-α-Induced IL-8 mRNA and
Protein Levels in HUVECs. The eﬀect of ticlopidine on the
IL-8 production of TNF-α stimulated HUVECs was also
examinedsimultaneously.ByusingspeciﬁcIL-8primers,RT-
PCR analysis detected a single band with the expected size
of 289bp. As shown in Figure 2(a), ticlopidine at 30μg/mL
strongly decreased the induction of IL-8 mRNA level in
HUVECs treated with TNF-α.T h eβ-actin gene ampliﬁ-
cation was included as the internal control to normalize
the gene expression. Moreover, real-time PCR experiment
showed the increased level of IL-8 mRNA expression uponJournal of Biomedicine and Biotechnology 5
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Figure 2: Reduction of IL-8 mRNA and protein levels by ticlopidine in HUVECs. HUVECs were incubated with serum-free medium for
12hours before diﬀerent concentrations of ticlopidine were added, after 12hours incubation cells were stimulated with/without TNF-α
(10ng/mL) for another 24hours. (a) Total RNA was extracted and analyzed by RT-PCR. Lane 1, without TNF-α;l a n e2 ,T N F - α (10ng/mL)
alone; lane 3, TNF-α + ticlopidine (0.1μg/mL); lane 4 TNF-α + ticlopidine (30μg/mL); M denotes molecular size marker. The lower panel
is β-actin as the internal control. Results are representative one of three independent experiments. (b) Relative amount of IL-8 mRNA level
was determined by quantitative real-time RT-PCR. (c) Culture supernatants were analyzed by ELISA. Data are expressed as the mean ± SEM
of duplicate wells and are representative of six individual experiments. Signiﬁcantly diﬀerent versus TNF-treated alone ∗P < .05, ∗∗P < .001.
TNF-α treatment, and decreased at diﬀerent ticlopidine
concentrations tested (Figure 2(b)). Similarly, TNF-α up-
regulated the level of IL-8 (47,830 ± 9,882pg/mL) secretion
in HUVECs as compared to that in samples without TNF-α
treatment (8,494 ± 801 pg/mL, n = 6) (P = .0078). TNF-
α-timulated IL-8 secretion was reduced (Figure 2(c)) when
cells were pretreated with ticlopidine in a dose dependent
way. Doses of ticlopidine at as low as 2μg/mL signiﬁcantly
(P = .0135) decreased IL-8 secretion by 31.9% (32,580 ±
8,711pg/mL) presumably due to the reduction in the steady-
state level of IL-8 mRNA (Figure 2(b)). Taken together, our
data suggested ticlopidine declined IL-8 mRNA and protein
levels in TNF-α stimulated HUVECs.
3.3. Reduction of VCAM-1 mRNA and Protein Levels on TNF-
αTreatedHUVECsbyTiclopidine. Toexaminewhetherticlo-
pidine could aﬀect VCAM-1 level, we assayed the VCAM-1
level by real-time PCR and ELISA. VCAM-1 mRNA level was
downregulatedatdiﬀerentticlopidineconcentrationstreated
(Figure 3(a)). As shown in Figure 3(b), ticlopidine declined
VCAM-1 protein levels in a dose-dependent manner. Ticlo-
pidine at 2, 10, and 30μg/mL signiﬁcantly decreased TNF-α
induced VCAM-1 levels to 624.3 ± 71.34pg/mL (P = .04),
288.3 ± 32.45pg/mL (P < .001), and 62.0 ± 5.86pg/mL (P
< .001), respectively, as compared to TNF-α treated alone
(836.0 ± 56.45pg/mL). The VCAM-1 levels analyzed by
ﬂow cytometry (data not shown) were consistent with those
measured using the ELISA method.
3.4. Reduction of U937 Cell Adhesion to TNF-Treated
HUVECs by Ticlopidine. The human premonocytic cell line
U937 [38] has been extensively used to investigate leucocyte-
endothelial cell interaction [39]. Studies demonstrated IL-
8 and MCP-1 receptors; CXCR2 and CCR2B mRNAs were
detected in U937 cells [40]. Adhesion of human premono-
cytic U937 cells to HUVECs, in our study, showed that
TNF-α signiﬁcantly (P < .001) enhanced U937 adhesion
(594.6 ± 120.0%) as compared to medium alone (100%).
Ticlopidine induced a dose-dependent reduction of TNF-
induced adhesion (Figure 4). It at as low as 0.1μg/mL6 Journal of Biomedicine and Biotechnology
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Figure 3: Reduction of VCAM-1 mRNA and protein levels by ticlopidine in HUVECs. HUVECs were incubated with serum-free medium
for 12hours before diﬀerent concentrations of ticlopidine were added, after 12hours incubation cells were stimulated with/without TNF-
α (10ng/mL) for another 24hours. (a) Relative amount of VCAM-1 mRNA level was determined by quantitative real-time RT-PCR. (b)
Culture supernatants were analyzed by ELISA. Data are expressed as the mean ± SEM of duplicate wells and are representative of three
individual experiments. Signiﬁcantly diﬀerent versus TNF-treated alone ∗P < .05, ∗∗P < .001.
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Figure 4: Reduction of monocyte (U937) adhesion by ticlopidine.
HUVECs were incubated with serum-free medium for 12hours
before diﬀerent concentrations of ticlopidine were added, after
12hours incubation cells were stimulated with/without TNF-α
(10ng/mL) for another 24hours. Adhesion of ﬂuorescence-labeled
U937 cells was determined by adhesion assay. Data are expressed
as the mean ± SEM of ﬁve individual experiments. Signiﬁcantly
diﬀerent versus TNF-treated alone ∗P < .05, ∗∗P < .001.
decreased TNF-α-induced U937 cells adhesion by 347.7 ±
70.88% (P = .032).
3.5. Reduction of U937 Cell Chemotaxis by Ticlopidine. To
investigate whether ticlopidine could mediate chemoattrac-
tant in response to chemokines, we investigated whether
ticlopidine might modulate chemotaxis under TNF-α stim-
ulation. As shown in Figure 5, recombinant MCP-1 and IL-
8( 5 0μg/mL) increased U937 cells chemotaxis to the lower
wellsascomparedtomediumalone.Ticlopidine at2,10,and
30μg/mL concentrations signiﬁcantly (P = .0497, .0352, and
.0352, resp.) inhibited the U937 cell chemotaxis to the lower
wells (Figure 5).
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Figure 5: Reduction of U937 cells chemotaxis by ticlopidine.
HUVECs were incubated at the upper wells of the transwell
plates until conﬂuency, then diﬀerent concentrations of ticlopidine
were added. After 30minutes of incubation, cells were stimulated
with/without TNF-α (10ng/mL). U937 cells were added to the
upper chamber wells and incubated for 1.5hours. The cells
chemotastic to the lower wells were counted. Data are expressed
as the mean ± SEM of three individual experiments. Signiﬁcantly
diﬀerent versus TNF-treated alone ∗P < .05, ∗∗P < .001.
3.6. Translocation of NF-kB p65 Was Not Aﬀe c t e db yT i c l o -
pidine. To test whether ticlopidine could inhibit NF-kB
translocation and subsequently reduce IL-8 and MCP-1
levels, a Western blot was performed. Western analysis of
nuclear protein NF-kB p65 subunit translocation had shown
that ticlopidine at all concentrations tested had no eﬀect
on p65 subunit translocation (Figure 6(a)). In contrast,
aspirin (100μg/mL) is known to inhibit NF-kB p65 subunit
translocation [35, 41]. B23, a major nucleolar protein, was
included as the loading control. In the cytoplasm, TNF-
α treatment resulted in complete degradation of IkB-α inJournal of Biomedicine and Biotechnology 7
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Figure 6: Ticlopidine has no eﬀect on NF-kB activation. HUVECs were incubated with diﬀerent concentrations of ticlopidine, and
100μg/mL of aspirin was added as the control. Cells were stimulated with/without TNF-α (10ng/mL) for 30 minutes, nuclear and cytosolic
proteins were collected. Brieﬂy, the nuclear protein extracts were collected, and western blots were performed using anti-NFkB p65 and
anti-B23 Ab (a). Cytosolic protein extracts were collected, and western blots were performed using anti-Ik-B-α and α-tubulin Ab (b). Lane 1,
withoutTNF-α;lane2,TNF -α(10ng/mL)alo ne;lane3,TNF -α+aspirin(100μg/mL);lane4,TNF-α+ticlopidine(1μg/mL);lane5,TNF-α
+ ticlopidine (10μg/mL); lane 6, TNF-α + ticlopidine (30μg/mL). Results are representative of one of three independent experiments.
H U V E C sa sc o m p a r e dt oc o n t r o l( Figure 6(b),l a n e2 ) .
Aspirin has been shown to inhibit activation of NF-kB
by preventing alteration of IkB-α (Figures 6(a) and 6(b),
lane 3) [41]. We found that IkB-α was undetectable under
diﬀerent concentrations of ticlopidine treatment. α-tubulin
was included as the loading control in cytoplasm. Therefore,
our ﬁndings suggest that the reduction of IL-8 and MCP-1
by ticlopidine may not occur through the inhibition of NF-
kB p65 subunit translocation.
4. Discussion
Atherosclerosis and its associated complications continue
to represent major causes of morbidity and mortality
in the industrialized or Western countries. Inﬂammation
and leukocyte recruitment play an important role in the
pathogenesis of atherosclerosis [42]. Because there is lack
of eﬀective drugs for atherosclerosis regression, the current
standard therapy for atherosclerosis-related diseases mainly
relies on antiplatelet agents, including ticlopidine. Platelet
interaction with leukocytes may be crucial for the initiation
of inﬂammation [43–45]. Platelets are involved in various
phases of atherothrombosis, including the initial steps of
atherogenesis, the progression of atherosclerotic lesions, and
the ensuing thrombotic complications. Studies have demon-
strated that platelet-endothelial interaction also triggers a
local inﬂammatory reaction that contributes to microcir-
culatory impairment and an acceleration of atherosclerotic
lesion progression in the macrovasculature [46].
On the other hand, MCP-1 and IL-8 levels were ele-
vated in lesions with monocyte inﬁltration [13, 19]. Both
increased MCP-1 and IL-8 levels have been observed in
patients with acute coronary syndromes. The elevation
of those and other possible chemokines can be used to
predict overall atherosclerotic burden [47]. In Figures 1
and 2 we showed that ticlopidine signiﬁcantly decreased
TNF-α-induced MCP-1 and IL-8 levels in HUVECs and
monocyte adhesion onto endothelial cells. According to
previous studies [8, 48], cytokine–activated endothelial cells
may secrete monocyte-speciﬁc chemoattractant molecules,
to amass monocytes at sites of vascular injury and/or
inﬂammation such as atherosclerosis.
MCP-1-deﬁcient mice deposit fewer lipids and have
fewer macrophages within the aortic walls after LDL
receptor-deﬁcient mice have been fed with a high cholesterol
diet [49]. Mice lacking one of the MCP-1 receptors, CCR-
2 showed an overall decrease in atherosclerotic lesion size
[50, 51]. Further, macrophages and monocytes were less
signiﬁcantly present in the aorta of CCR-2-deﬁcient mice
although the overall plasma cholesterol levels were unaf-
fected by the CCR-2 genotype. Blocking CCR-2 and CXCR-
3h a sd i ﬀerential eﬀects during atherogenesis [52]. These
data suggest that MCP-1 plays a crucial role in initiating
atherosclerosis by recruiting macrophages and monocytes to
the vessel wall, and that the process of monocyte recruitment
is a major determinant of lesion size.
IL-8 belongs to ELR+ CXC chemokines family which
plays a role in neutrophil chemotaxis and regulates CXC
chemokine-induced angiogenesis [53, 54] .Ap r e v i o u ss t u d y
showed that the CXC chemokine receptor 2, CXCR2, is
the putative receptor for ELR+ CXC chemokine-mediated
angiogenesis [55]. IL-8, shown to be an angiogenic factor
in vivo and a chemotactic and mitogenic factor for vascular
smooth muscle and endothelial cells in vitro, is remarkably
elevated in atherectomized specimens and may be a primary
signal for angiogenesis in artherosclerotic tissue [56]. IL-8,
which is found colocalized with vascular endothelial cells,
supports a role for chemokines in atherogenesis, and, in
turn, may contribute to the development and progression of
coronary atherosclerotic disease in humans [56].
Ticlopidine, an antiplatelet drug, was clinically used
for the secondary prevention of transient ischemic attacks
(TIA), ischemic stroke, and coronary heart diseases, which
are closely associated with atherosclerosis [19, 20]. Several
clinical studies of ticlopidine in the prevention of stroke8 Journal of Biomedicine and Biotechnology
have shown it to be an eﬀective prophylactic agent not only
in patients with previous transient cerebral ischemia but
also in patients with a previous complete stroke [26, 57].
Recently, studies revealed ticlopidine attenuates progression
of atherosclerosis in apolipoprotein E and low density
lipoprotein receptor double knockout (apoE/LDLR-/-) mice
and improve the endothelial function in those mice [58].
The size of the atherosclerotic plaques and the number
of macrophages were signiﬁcantly reduced by ticlopidine
treated mice as compared to their nontreated counterparts.
Thus, ticlopidine treatment limited the vascular inﬂamma-
toryresponseofatherosclerosisinadditiontotheantiplatelet
eﬀects.
In examining ticlopidine’s eﬀects on TNF-α-induced
levels of MCP-1 and IL-8 chemokines and VCAM-1 in
HUVECs, we found that ticlopidine lowered both the mRNA
and protein levels of MCP-1, IL-8, and VCAM-1. Studies
suggested that aspirin also suppresses monocyte adhesion
and chemotaxis to endothelial cells. Aspirin is widely used
as an antiinﬂammatory, antithrombotic, and even an anti-
malignant agent. It was found to inactivate the transcription
factor, NF-kB, which contains a DNA-binding domain for
consensus sequences of various cytokines and chemokines
including MCP-1 and IL-8 [59–62]. Studies showed inhi-
bition of NF-kB attenuated atherosclerosis in apoE/LDLR
double knockout mice [63]. Therefore, aspirin may inhibit
NF-kB activities and then decrease chemokine expression
(Figure 5). However, we found ticlopidine failed to inhibit
the translocation of NF-kB into the nucleus. Therefore, the
reduction of MCP-1 and IL-8 by ticlopidine may occur
through an NF-kB-independent pathway.
Taking all the ﬁndings together, we suggest that ticlo-
pidine may decline atherosclerotic process by blocking the
crucial step of monocyte adhesion and migration through
reducing MCP-1, IL-8, and VCAM-1 level in cytokine-
stimulated endothelial cells, and this eﬀect does not occur
through NF-kB inhibition.
Acknowledgments
This study was supported by a Grant from the National
Science Council of Taiwan, Grants NSC 96-2314-B-038-022
and NSC 97-2314-038-004-MY3 (Dr. S-J. Leu). The authors
thank Dr. Fang Liao from Academic Sinica, Taipei, Taiwan
for his assistance in migration assay.
References
[1] R. Terkeltaub, W. A. Boisvert, and L. K. Curtiss, “Chemokines
and atherosclerosis,” Current Opinion in Lipidology, vol. 9, no.
5, pp. 397–405, 1998.
[2] T. J. Reape and P. H. E. Groot, “Chemokines and atherosclero-
sis,” Atherosclerosis, vol. 147, no. 2, pp. 213–225, 1999.
[3] C. Dosquet, D. Weill, and J. L. Wautier, “Cytokines and
thrombosis,” Journal of Cardiovascular Pharmacology, vol. 25,
supplement 2, pp. S13–S19, 1995.
[4] V. Braunersreuther, F. Mach, and S. Steﬀens, “The speciﬁc role
of chemokines in atherosclerosis,” Thrombosis and Haemosta-
sis, vol. 97, no. 5, pp. 714–721, 2007.
[ 5 ]M .N a v a b ,S .S .I m e s ,S .Y .H a m a ,e ta l . ,“ M o n o c y t et r a n s m i -
gration induced by modiﬁcation of low density lipoprotein in
cocultures of human aortic wall cells is due to induction of
monocyte chemotactic protein 1 synthesis and is abolished by
high density lipoprotein,” Journal of Clinical Investigation, vol.
88, no. 6, pp. 2039–2046, 1991.
[6] D. H. Adams and A. R. Lloyd, “Chemokines: leucocyte
recruitment and activation cytokines,” The Lancet, vol. 349,
no. 9050, pp. 490–495, 1997.
[7] M.Baggiolini,B.Dewald,andB.Moser,“Humanchemokines:
an update,” Annual Review of Immunology, vol. 15, pp. 675–
705, 1997.
[8] A. Sica, J. M. Wang, F. Colotta, et al., “Monocyte chemotactic
and activating factor gene expression induced in endothelial
c e l l sb yI L - 1a n dt u m o rn e c r o s i sf a c t o r , ”Journal of Immunol-
ogy, vol. 144, no. 8, pp. 3034–3038, 1990.
[9] B. J. Rollins, T. Yoshimura, E. J. Leonard, and J. S. Pober,
“Cytokine-activated human endothelial cells synthesize and
secrete a monocyte chemoattractant, MCP-1/JE,” American
Journal of Pathology, vol. 136, no. 6, pp. 1229–1233, 1990.
[10] J. A. Satriano, M. Shuldiner, K. Hora, Y. Xing, and Z. Shan,
“Oxygen radicals as second messengers for expression of
the monocyte chemoattractant protein, JE/MCP-1, and the
monocyte colony-stimulating factor, CSF-1, in response to
t u m o rn e c r o s i sf a c t o r - α and immunoglobulin G. Evidence for
involvement of reduced nicotinamide adenine dinucleotide
phosphate (NADPH)-dependent oxidase,” Journal of Clinical
Investigation, vol. 92, no. 3, pp. 1564–1571, 1993.
[11] S. Yla-Herttuala, B. A. Lipton, M. E. Rosenfeld, et al., “Expres-
sion of monocyte chemoattractant protein 1 in macrophage-
rich areas of human and rabbit atherosclerotic lesions,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 88, no. 12, pp. 5252–5256, 1991.
[12] N. A. Nelken, S. R. Coughlin, D. Gordon, and J. N. Wilcox,
“Monocyte chemoattractant protein-1 in human atheroma-
tous plaques,” Journal of Clinical Investigation,v o l .8 8 ,n o .4 ,
pp. 1121–1127, 1991.
[13] M. Takeya, T. Yoshimura, E. J. Leonard, and K. Takahashi,
“Detection of monocyte chemoattractant protein-1 in human
atherosclerotic lesions by an anti-monocyte chemoattractant
protein-1 monoclonal antibody,” Human Pathology, vol. 24,
no. 5, pp. 534–539, 1993.
[14] Y. Seino, U. Ikeda, M. Takahashi, et al., “Expression of mono-
cyte chemoattractant protein-1 in vascular tissue,” Cytokine,
vol. 7, no. 6, pp. 575–579, 1995.
[15] M. Baggiolini, B. Dewald, and B. Moser, “Interleukin-8 and
related chemotactic cytokines—CXC and CC chemokines,”
Advances in Immunology, vol. 55, pp. 97–179, 1994.
[16] W.A.Boisvert,R.Santiago,L.K.Curtiss,andR.A.Terkeltaub,
“A leukocyte homologue of the IL-8 receptor CXCR-2 medi-
ates the accumulation of macrophages in atherosclerotic
lesions of LDL receptor-deﬁcient mice,” Journal of Clinical
Investigation, vol. 101, no. 2, pp. 353–363, 1998.
[ 1 7 ] W .A .B o i s v e r t ,L .K .C u r t i s s ,a n dR .A .T e r k e l t a u b ,
“Interleukin-8 and its receptor CXCR2 in atherosclerosis,”
Immunologic Research, vol. 21, no. 2-3, pp. 129–137, 2000.
[18] E. R. Gonzalez and B. S. Kannewurf, “Atherosclerosis: a uni-
fying disorder with diverse manifestations,” American Journal
of Health-System Pharmacy, vol. 55, no. 19, supplement 1, pp.
S4–S7, 1998.
[ 1 9 ]A .E .K o c h ,S .L .K u n k e l ,W .H .P e a r c e ,e ta l . ,“ E n h a n c e d
production of the chemotactic cytokines interleukin-8 and
monocyte chemoattractant protein-1 in human abdominalJournal of Biomedicine and Biotechnology 9
aortic aneurysms,” American Journal of Pathology, vol. 142, no.
5, pp. 1423–1431, 1993.
[20] S. Blankenberg, S. Barbaux, and L. Tiret, “Adhesion molecules
and atherosclerosis,” Atherosclerosis, vol. 170, no. 2, pp. 191–
203, 2003.
[ 2 1 ]J .T i a n ,H .P e i ,J .C .J a m e s ,e ta l . ,“ C i r c u l a t i n ga d h e s i o n
molecules in apoE-deﬁcient mouse strains with diﬀerent
atherosclerosis susceptibility,” Biochemical and Biophysical
Research Communications, vol. 329, no. 3, pp. 1102–1107,
2005.
[22] C. L. Ramos, Y. Huo, U. Jung, et al., “Direct demonstration of
P-selectin- and VCAM-1-dependent mononuclear cell rolling
in early atherosclerotic lesions of apolipoprotein E-deﬁcient
mice,” Circulation Research, vol. 84, no. 11, pp. 1237–1244,
1999.
[23] K. D. O’Brien, M. D. Allen, T. O. McDonald, et al., “Vascular
cell adhesion molecule-1 is expressed in human coronary
atherosclerotic plaques: implications for the mode of progres-
sion of advanced coronary atherosclerosis,” Journal of Clinical
Investigation, vol. 92, no. 2, pp. 945–951, 1993.
[24] M. I. Cybulsky, K. Iiyama, H. Li, et al., “A major role for
VCAM-1, but not ICAM-1, in early atherosclerosis,” Journal
of Clinical Investigation, vol. 107, no. 10, pp. 1255–1262, 2001.
[25] M. J. Quinn and D. J. Fitzgerald, “Ticlopidine and clopido-
grel,” Circulation, vol. 100, no. 15, pp. 1667–1672, 1999.
[26] M. Gent, J. A. Blakely, J. D. Easton, et al., “The Canadian
American Ticlopidine Study (CATS) in thromboembolic
stroke,” The Lancet, vol. 1, no. 8649, pp. 1215–1220, 1989.
[27] A. Bellavance, “Eﬃcacy of ticlopidine and aspirin for pre-
vention of reversible cerebrovascular ischemic events. The
Ticlopidine Aspirin Stroke Study,” Stroke, vol. 24, no. 10, pp.
1452–1457, 1993.
[28] Y.-Y. Yang, C.-J. Hu, S.-M. Chang, T.-Y. Tai, and S.-J.
Leu, “Aspirin inhibits monocyte chemoattractant protein-1
and interleukin-8 expression in TNF-α stimulated human
umbilical vein endothelial cells,” Atherosclerosis, vol. 174, no.
2, pp. 207–213, 2004.
[29] I. M. Hayes, N. J. Jordan, S. Towers, et al., “Human vascular
smooth muscle cells express receptors for CC chemokines,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no.
3, pp. 397–403, 1998.
[30] S. Lagoo-Deenadayalan, A. S. Lagoo, W. H. Barber, and K. J.
Hardy, “A standardized approach to PCR-based semiquanti-
tation of multiple cytokine gene transcripts from small cell
samples,”LymphokineandCytokineResearch,v ol.12,no .2,pp .
59–67, 1993.
[31] J. L. Stern and B. Slobedman, “Human cytomegalovirus latent
infection of myeloid cells directs monocyte migration by
up-regulating monocyte chemotactic protein-1,” Journal of
Immunology, vol. 180, no. 10, pp. 6577–6585, 2008.
[32] T. B. Huber, H. C. Reinhardt, M. Exner, et al., “Expres-
sion of functional CCR and CXCR chemokine receptors in
podocytes,” Journal of Immunology, vol. 168, no. 12, pp. 6244–
6252, 2002.
[ 3 3 ]M .I .S a n t o s ,S .F u c h s ,M .E .G o m e s ,R .E .U n g e r ,R .L .R e i s ,
and C. J. Kirkpatrick, “Response of micro- and macrovascular
endothelial cells to starch-based ﬁber meshes for bone tissue
engineering,” Biomaterials, vol. 28, no. 2, pp. 240–248, 2007.
[34] K.-L. Chen, W.-H. Liu, Y.-Y. Yang, S.-J. C. Leu, and N.-Y. Shih,
“Characterization of novel transforming growth factor-beta
type I receptors found in malignant pleural eﬀusion tumor
cells,” BMC Molecular Biology, vol. 8, article 72, 2007.
[35] C. Weber, W. Erl, A. Pietsch, and P. C. Weber, “Aspirin inhibits
nuclear factor-κB mobilization and monocyte adhesion in
stimulated human endothelial cells,” Circulation, vol. 91, no.
7, pp. 1914–1917, 1995.
[36] C. Klein-Soyer, J.-P. Cazenave, J.-M. Herbert, and J.-P. Maf-
frand, “SR 25989 inhibits healing of a mechanical wound of
conﬂuent human saphenous vein endothelial cells which is
modulated by standard heparin and growth factors,” Journal
of Cellular Physiology, vol. 160, no. 2, pp. 316–322, 1994.
[37] T. Di Perri, F. L. Pasini, C. Frigerio, et al., “Pharmacodynamics
of ticlopidine in man in relation to plasma and blood cell
concentration,” European Journal of Clinical Pharmacology,
vol. 41, no. 5, pp. 429–434, 1991.
[38] P. Harris and P. Ralph, “Human leukemic models of
myelomonocytic development: a review of the HL-60 and
U937 cell lines,” J o u r n a lo fL e u k o c y t eB i o l o g y , vol. 37, no. 4,
pp. 407–422, 1985.
[39] D. Carvalho, C. O. S. Savage, C. M. Black, and J. D.
Pearson, “IgG antiendothelial cell autoantibodies from scle-
roderma patients induce leukocyte adhesion to human
vascular endothelial cells in vitro: induction of adhesion
molecule expression and involvement of endothelium-derived
cytokines,” Journal of Clinical Investigation,v o l .9 7 ,n o .1 ,p p .
111–119, 1996.
[40] D. A. Lazzarino, M. de Diego, S. Z. Hirschman, et al., “IL-
8 and MCP-1 secretion is enhanced by the peptide-nucleic
acidimmunomodulator,productR,inU937cellsandprimary
human monocytes,” Cytokine, vol. 14, no. 4, pp. 234–239,
2001.
[41] E. Kopp and S. Ghosh, “Inhibition of NF-κBb ys o d i u m
salicylateandaspirin,”Science,vol.265,no.5174,pp.956–959,
1994.
[ 4 2 ]M .N a v a b ,S .Y .H a m a ,T .B .N g u y e n ,a n dA .M .F o g e l m a n ,
“Monocyte adhesion and transmigration in atherosclerosis,”
Coronary Artery Disease, vol. 5, no. 3, pp. 198–204, 1994.
[43] D. I. Siegel-Axel and M. Gawaz, “Platelets and endothelial
cells,” Seminars in Thrombosis and Hemostasis,v o l .3 3 ,n o .2 ,
pp. 128–135, 2007.
[44] A. E. May, H. Langer, P. Seizer, B. Bigalke, S. Lindemann, and
M. Gawaz, “Platelet-leukocyte interactions in inﬂammation
and atherothrombosis,” Seminars in Thrombosis and Hemosta-
sis, vol. 33, no. 2, pp. 123–127, 2007.
[45] M. Gawaz, H. Langer, and A. E. May, “Platelets in inﬂamma-
tion and atherogenesis,” Journal of Clinical Investigation, vol.
115, no. 12, pp. 3378–3384, 2005.
[46] S. R. Steinhubl and D. J. Moliterno, “The role of the platelet
in the pathogenesis of atherothrombosis,” American Journal of
Cardiovascular Drugs, vol. 5, no. 6, pp. 399–408, 2005.
[47] R. E. Gerszten, F. Mach, A. Sauty, A. Rosenzweig, and A. D.
Luster, “Chemokines, leukocytes, and atherosclerosis,” Journal
of Laboratory and Clinical Medicine, vol. 136, no. 2, pp. 87–92,
2000.
[48] B.J.Rollins,“Monocytechemoattractantprotein1:apotential
regulator of monocyte recruitment in inﬂammatory disease,”
Molecular Medicine Today, vol. 2, no. 5, pp. 198–204, 1996.
[49] L. Gu, Y. Okada, S. K. Clinton, et al., “Absence of monocyte
chemoattractant protein-1 reduces atherosclerosis in low
density lipoprotein receptor-deﬁcient mice,” Molecular Cell,
vol. 2, no. 2, pp. 275–281, 1998.
[50] L. Boring, J. Gosling, S. W. Chensue, et al., “Impaired
monocyte migration and reduced type 1 (Th1) cytokine
responses in C-C chemokine receptor 2 knockout mice,”
Journal of Clinical Investigation, vol. 100, no. 10, pp. 2552–
2561, 1997.
[51] L. Boring, J. Gosling, M. Cleary, and I. F. Charo, “Decreased
lesion formation in CCR2−/− mice reveals a role for10 Journal of Biomedicine and Biotechnology
chemokines in the initiation of atherosclerosis,” Nature, vol.
394, no. 6696, pp. 894–897, 1998.
[52] N.R.Veillard,S.Steﬀens,G.Pelli,etal.,“Diﬀerentialinﬂuence
of chemokine receptors CCR2 and CXCR3 in development of
atherosclerosis in vivo,” Circulation, vol. 112, no. 6, pp. 870–
878, 2005.
[53] R. M. Strieter, P. J. Polverini, S. L. Kunkel, et al., “The
functional role of the ELR motif in CXC chemokine-mediated
angiogenesis,” Journal of Biological Chemistry, vol. 270, no. 45,
pp. 27348–27357, 1995.
[54] J. A. Belperio, M. P. Keane, D. A. Arenberg, et al., “CXC
chemokines in angiogenesis,” Journal of Leukocyte Biology, vol.
68, no. 1, pp. 1–8, 2000.
[55] C. L. Addison, T. O. Daniel, M. D. Burdick, et al., “The CXC
chemokine receptor 2, CXCR2, is the putative receptor for
ELR+ CXCchemokine-inducedangiogenicactivity,”Journalof
Immunology, vol. 165, no. 9, pp. 5269–5277, 2000.
[56] A. Simonini, M. Moscucci, D. W. M. Muller, et al., “IL-8 is
an angiogenic factor in human coronary atherectomy tissue,”
Circulation, vol. 101, no. 13, pp. 1519–1526, 2000.
[57] W. K. Hass, J. D. Easton, H. P. Adams Jr., et al., “A randomized
trial comparing ticlopidine hydrochloride with aspirin for
the prevention of stroke in high-risk patients,” New England
Journal of Medicine, vol. 321, no. 8, pp. 501–507, 1989.
[58] J. Jawien, G. Csanyi, M. Gajda, L. Mateuszuk, and M. Lom-
nicka, “Ticlopidine attenuates progression of atherosclerosis
in apolipoprotein E and low density lipoprotein receptor
double knockout mice,” European Journal of Pharmacology,
vol. 556, no. 1–3, pp. 129–135, 2007.
[ 5 9 ]C .K u n s c ha n dC .A .R o s e n ,“ N F - κB subunit-speciﬁc regu-
lation of the interleukin-8 promoter,” Molecular and Cellular
Biology, vol. 13, no. 10, pp. 6137–6146, 1993.
[60] K. Yasumoto, S.-I. Okamoto, N. Mukaida, S. Murakami, M.
Mai, and K. Matsushima, “Tumor necrosis factor α and
interferon γ synergistically induce interleukin 8 production in
a human gastric cancer cell line through acting concurrently
on AP-1 and NF-kB-like binding sites of the interleukin 8
gene,” Journal of Biological Chemistry, vol. 267, no. 31, pp.
22506–22511, 1992.
[ 6 1 ]R .R .F r e t e r ,J .A .A l b e r t a ,G .Y .H w a n g ,A .L .W r e n t m o r e ,
and C. D. Stiles, “Platelet-derived growth factor induction of
the immediate-early gene MCP-1 is mediated by NF-κBa n d
a 90-kDa phosphoprotein coactivator,” Journal of Biological
Chemistry, vol. 271, no. 29, pp. 17417–17424, 1996.
[62] A. Amberger, M. Hala, M. Saurwein-Teissl, et al., “Suppressive
eﬀects of anti-inﬂammatory agents on human endothelial cell
activation and induction of heat shock proteins,” Molecular
Medicine, vol. 5, no. 2, pp. 117–128, 1999.
[63] J.Jawien,M.Gajda,L.Mateuszuk,etal.,“Inhibitionofnuclear
factor-κB attenuates artherosclerosis in apoE/LDLR—double
knockout mice,” Journal of Physiology and Pharmacology, vol.
56, no. 3, pp. 483–489, 2005.